Beyond the randomized clinical trials comes the real-world evidence

Sofia, November 14, 2022 – Dr. Gergana Shalamanova from the Oncology Center in Plovdiv showed the interesting comparison of Real-world Evidence (RWE) vs. Randomized Clinical Trials at the Second National Congress in Dermatooncology.

The results of BRAF inhibitors’ registrational clinical trials have been externally validated to the real-world population of patients with BRAF+ melanoma using Sqilline Danny Platform.

The efficacy of certain targeted therapies in BRAF+ melanoma patients is better in real-world settings compared to the results of two randomized clinical trials with differences of:

  • 20 and 24% in progression-free survival (PFS) at 12 months;
  • 12 and 13% in overall survival (OS) at 12 months.

Beyond the randomized clinical trials comes the real-world evidence… Danny Platform compares both and shows higher efficacy of targeted therapies in real-world BRAF+ melanoma patients,” said Dr. Shalamanova.

These findings open discussion for the wider use of technology in generating Real-world Evidence (RWE) to assess treatment outcomes in real-world settings.

Sqilline Danny Platform proves to be a highly effective technology to collect, process, and analyze Real-world Data (RWD) from Electronic Health Records (EHRs) and turning it into RWE.

Curious to learn more? Get in touch with our team! https://sqilline.com/contact-us/

Share this article:

More News & Highlights

Highlights

Sqilline Scientific Research Project Flow

Is there a clinical problem you want to solve? Do you have a hypothesis you want to test? Do you want to clarify your research...

Read more...

Highlights

Health data as an infrastructure

Health data can be considered a crucial component of healthcare infrastructure, as it forms the basis for decision-making, research, policy development, and patient care within...

Read more...

News

Lung Cancer Real-world Evidence Secondary Use of Data: A Non-Interventional Study

Description of clinical study: Non-Interventional Study for Analysis of Molecular Diagnostics and Treatment Patterns in Metastatic Non-Small Cell Lung Cancer Patients (Newly Diagnosed and Relapses...

Read more...